{"name":"Guardant Health","slug":"guardant","ticker":"GH","exchange":"NASDAQ","domain":"guardanthealth.com","description":"Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.","hq":"Palo Alto, CA","founded":0,"employees":"2490","ceo":"Helmy Eltoukhy","sector":"Liquid Biopsy / Oncology Diagnostics","stockPrice":98.23,"stockChange":-0.24,"stockChangePercent":-0.24,"marketCap":"$13.0B","metrics":{"revenue":1080215040,"revenueGrowth":48.3,"grossMargin":64.9,"rdSpend":364191000,"netIncome":-416277000,"cash":1102759936,"dividendYield":0,"peRatio":-155,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Lynparza patent cliff ($1.4B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Guardant Health reported revenue of $434.8 million for the fourth quarter and $1.6 billion for the full year 2023, representing year-over-year growth of 34% and 43%, respectively.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Guardant Health and AstraZeneca Announce Collaboration to Develop Companion Diagnostic for Lynparza","summary":"Guardant Health and AstraZeneca have entered into a collaboration to develop a companion diagnostic for Lynparza, a PARP inhibitor for the treatment of ovarian cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Guardant Health Receives FDA Clearance for Guardant360 CDx for NSCLC","summary":"Guardant Health has received FDA clearance for its Guardant360 CDx test for non-small cell lung cancer (NSCLC), enabling the company to market the test as a companion diagnostic for targeted therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOZWxfalkyU3J1OVdOTGk0VTlEU0tpUnhiRWtZcHlrTEgxZTlodTFOV3J3X3l0LWhsZVp0UXVvQ1NVQmtITDU0ZHo5U2t4bWdsVHNuRnVEUTdXWUxqN2RYaVd4V0pEZ0hEN2dlWGhXVmc0a0VkTzBXQ0ljbGJmaFlwUnZNZlE2bFdtclM5NTVPOHlmei1ua0dISG1NeHFJc2R4OHQ2ZHhVOXVLeFJ4YnVMeU9FUGxuMXYwWWsycWZ0RmZhdm45cTVsdC1vX29hUE9qeGFZbGJudDVGUGpMZ1Z6dW5uZGoxQUJnbzBiVU9GNTNjZnhqVVpEazMzUXQ0TVBidWxpQXJn?oc=5","date":"2026-04-06","type":"pipeline","source":"TradingView","summary":"Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know - TradingView","headline":"Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQNE9rb0hlUG9RLVNiR3NmVHdJajRMc09SR01Zekxaa1RfQ3pmTm5HMVkzTVdGVkNpMFFCQjNmdU1LYjF5NEp4Q3pyVHlQMjRfZkpKSGlacEIwUkpiLVh6S0dWME5hTFRnVEh3WEl3ZFN5a1BPTy1OMGprR08yc3E4VWlzM1RMUU5lSGRUb0QtWjJzd3NiMEg5NkxaUEtjck5kYmwyeA?oc=5","date":"2026-04-02","type":"regulatory","source":"IndexBox","summary":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics - IndexBox","headline":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNVlFWVWgxRFpxME85WnFzX0xoc2JqeHhXbG5mcENaYVhXaHlPSW1na0RrTUNOVV9oWDJzcXVtNlM3NkN2OE9VWndTQ0Q2NFRXdWs2cWsyenFrdEZJNm53bDROVUhLWnVYaDRZcXVNVllkNmdCeTBNZ0ZDVHBYdWhLaC11amhUNWJJZV9Ebmh0cWJfNEZMd1E0Vi12QUpnUFZIS1BMZWE1Zjd0RUQ1SDZMLXhxQ2N5NkdYNEhiN1VMeHg2Y1E5dTFMQS1Pelo2bHloRTAyV253WEFSaGd5ejlObmdkYnFPSHlnalpNTnh2NDVOS2U5X0FSSGZJUQ?oc=5","date":"2026-03-04","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and 908 Devices (MASS) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and 908 Devices (MASS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxObm9aN1Bfdnc0VW1VS3pHTTh1QXlESGdTY1RyeXQzdkNfUzVyVlZoNTcxWFU2aTdyZ2VzaklDWHBYdU1aWmU3bXFWQjEzNTZTVWVCTmE1LWhHVy1EUUlFQVhUU1d1TzlfaTNNQ3R6cjVaajcwSnptM0JkNkNFYVBpZGFVTERpSTdwdFZucktfVlJhWnpDOUQxaVBNbk13YnVvQy1HTVFUb0VTMzEzWjk0WVQybkx3VnhnQVlhLXV6cUR1RjllcXpfQjRTQlktbGh5QWl3Q0Q1NTNXWF9ZRVAyWXBwTWZMMUk?oc=5","date":"2026-02-27","type":"pipeline","source":"Finviz","summary":"Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - Finviz","headline":"Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNLWx3TG1rT1pHMGJrUHVBaFZFejlnRUNHUW4ycVRRWmR3STlqWGtwNGFYWlQ1a3NRaVNMWS0ta0tRNHRJYnBGQkRMaEZwc1BFNks5WF9VUGxuZDlucTdhZ1JTUm1QdFhrTFR2VTR2NlRvd2FDNjhRTE43OENNWlJ6OWFxYk95bW9rQlJ3Rg?oc=5","date":"2026-02-12","type":"pipeline","source":"The Motley Fool","summary":"Top Cancer Stocks for 2026 and How to Invest - The Motley Fool","headline":"Top Cancer Stocks for 2026 and How to Invest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxONlh0M1JZOHp6UmxoQ2dkVFJURVBzczJLRmFDVmYxeHFNLWh2YWVRMlYza3VkSW15cWdINEwyM29xU1dFenBYUkVpRmpoZ0lkUnBwOU9wbVZrRDRvQ1VMM0w0VHhUclJ1LU04OUlnTWlDXy1jQzVRZ05zREF3TGR1N3pzWjdNU2RBS1JFMlU1bDlLclRJOGpvV0dHYjlVV21KNVRreHY0ZjFuRU1wXzh6TzE4OVhwc1NVSm9kdDgzcWdTdElKVk5pUjVuRExYWWJvMmFPRlRkXzk2Ml9RMU8wUVp1UTh5dmtPVkE?oc=5","date":"2026-01-29","type":"earnings","source":"Business Wire","summary":"Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire","headline":"Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUVN0V295clBwSnNINF82bXQ3ZTNYM3djemxwUU5FVG00d0JkaGJIVWpYd2l0X29ORzI2a245OFZtcksxS0Nfc2JSNEdTSVhiZXo4NC12clFpLTNwVmlwNjFQcjZORGJPckFWZEtzbzh2aEd4c2JNdDI1Y2pOa1lGbDljQTk1OXNTaUN4VThBeXk2d0dMQ3p4alQ0MG5VXzRyd2xTLUZSVzdEcnV2c0czR1YzakpsdVRYZnNB?oc=5","date":"2026-01-12","type":"earnings","source":"BioSpace","summary":"Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results - BioSpace","headline":"Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxONjhyb3dZOGlGb3Y0U3VsMUktZVg5U092R2w0YUdDY3NlR0sxS2ZMOFJad2IzMmVPamtzb01RamprOWUwS2ZnN0NWT29UanBJSWxiOGRLSks5RjVmMXR0bWtyWkIxcm9KMm1qMHhQM0ZodnplY1poM1ZhZFVoWWFxOUY0YkE1LW8?oc=5","date":"2025-12-04","type":"pipeline","source":"Yahoo Finance","summary":"Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance","headline":"Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPald6V0J6Z0g5Y1NMX3M0Y3pRTE5KOFVYYnZWWHBPNDJaVk5qQmYtLWp5aXNaWlI1TGxrd0s4aGJId0ZicXlpOXp3NmdMMGtPcTdhUklHWDV0eFNBUnBUWlRkM0JxeTB6V1RvaVg3NW1xZWo0bFRVN2lZdFlJTzVxVlU3eTdVYWRlNkpKSGplUjgwLXVRQk55Wk0tNDBQWU1uMWlYLTNxcGdJQ1FNMEhYM3hCRnVkRHA5TWc?oc=5","date":"2025-10-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Guardant and Zephyr AI pair up to advance cancer biomarker development - Pharmaceutical Technology","headline":"Guardant and Zephyr AI pair up to advance cancer biomarker development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPb21pVjh5cUhuRTFJYkFRRTBLZDUxVDA2cm1GdW5sbGVmbkNabE5YTUxfMGtFOVRJMWxSbTNDUVBEYWVabGQ5RjYxNWMtS0Z0TXZjd2JuZHNyenEtN2J2bjVwZlNPSzFXZXZuM3RLTmtPVUkwdmhLdks5MEVYYjVVV0U4aHlSdVlrZFVRaDlJZzByLU5haWZkNmhCLVZSRmJJYngw?oc=5","date":"2025-09-29","type":"deal","source":"The Pharma Letter","summary":"Taiho inks exploratory collaboration with Guardant Health - The Pharma Letter","headline":"Taiho inks exploratory collaboration with Guardant Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNQzZxT0tDbUw1Q01iMnAwNHMwUVlVTmdVbzd4Q2d1YUNTRUNrUmdtMGpwWlZrLVEyU0NOcWVyY1hWUTBuT1piUXNuOFdGZGJHZFZqQmcwWXUwS3I2WGZLZ2F0ZC1SM3VyWENvcl8xYkJxWUpBaW5lOE9qY0RubVVzZ2NwclpNNDlTbURsT2U5UVllWm1XckszbU1B?oc=5","date":"2025-03-29","type":"pipeline","source":"MarketBeat","summary":"4 Healthcare Stocks With Massive Gains—and More to Come - MarketBeat","headline":"4 Healthcare Stocks With Massive Gains—and More to Come","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPbUNHYUpqX1M0N1VvMVVYbTJOaExDZUVtakd1NUJYZWtwWnRsNDMzZVBVZkd3YXQ3ZTMyLVVIS3VBQ001N2ctbmg3dkVsazJGRkNDSjEtbVRpTzVTUW51VDloVXpJU29qUm1yU216eU9uNjdVcnFzRGZnSHFzZlcwSFoyY29CQVlRYV9fM2lscGtKZkplS0hTSUFaTjJIRmEwOUFuTkVtMFlRRXFVcmZoelRNUkJMX3J0MzdhdmdYN0FONnc4N1hHNk5MQnREbVdWTnNEUUpUZ3M2RXQ3RkxwN2VyLTdpYzlHN3h0RGczTkxodWllNXRVSTVrYw?oc=5","date":"2021-06-08","type":"regulatory","source":"Guardant Health Investor Relations","summary":"Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer - Guardant Health Investor Relations","headline":"Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer","sentiment":"neutral"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae","Exact Sciences"],"therapeuticFocus":["Oncology","Liquid Biopsy"],"financials":{"source":"sec_edgar+yahoo","revenue":982021000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":982021000,"period":"2025-12-31"},{"value":739016000,"period":"2024-12-31"},{"value":739016000,"period":"2024-12-31"},{"value":563948000,"period":"2023-12-31"},{"value":563948000,"period":"2023-12-31"}],"grossProfit":633014000,"grossProfitHistory":[{"period":"2025-12-31","value":633014000},{"period":"2024-12-31","value":449217000},{"period":"2023-12-31","value":336896000},{"period":"2022-12-31","value":293213000}],"rdSpend":364191000,"rdSpendHistory":[{"period":"2025-12-31","value":364191000},{"period":"2024-12-31","value":347753000},{"period":"2023-12-31","value":367194000},{"period":"2022-12-31","value":373807000}],"sgaSpend":706071000,"operatingIncome":-437248000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-437248000},{"period":"2024-12-31","value":-443594000},{"period":"2023-12-31","value":-564725000},{"period":"2022-12-31","value":-544378000}],"netIncome":-416277000,"netIncomeHistory":[{"period":"2025-12-31","value":-416277000},{"period":"2024-12-31","value":-436373000},{"period":"2023-12-31","value":-479449000},{"period":"2022-12-31","value":-654588000}],"eps":-3.32,"epsHistory":[{"period":"2025-12-31","value":-3.32},{"period":"2024-12-31","value":-3.56},{"period":"2023-12-31","value":-4.28},{"period":"2022-12-31","value":-6.41}],"cash":378203000,"cashHistory":[{"period":"2025-12-31","value":378203000},{"period":"2024-12-31","value":525540000},{"period":"2023-12-31","value":1133537000},{"period":"2022-12-31","value":141647000}],"totalAssets":2013659000,"totalLiabilities":2112966000,"totalDebt":1710142000,"equity":-99307000,"operatingCashflow":-184760000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-184760000},{"period":"2024-12-31","value":-239858000},{"period":"2023-12-31","value":-324975000},{"period":"2022-12-31","value":-309463000}],"capex":-48306000,"capexHistory":[{"period":"2025-12-31","value":-48306000},{"period":"2024-12-31","value":-35085000},{"period":"2023-12-31","value":-20486000},{"period":"2022-12-31","value":-77461000}],"freeCashflow":-233066000,"dividendsPaid":null,"buybacks":-45010000,"employees":2490,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":227058000,"ebit":-110356000,"ebitda":-100914000,"period":"2026-03-31","revenue":301665000,"epsBasic":-0.85,"netIncome":-112075000,"rdExpense":91038000,"epsDiluted":-0.85,"grossProfit":196746000,"operatingIncome":-121350000},{"sga":204315000,"ebit":-129041000,"ebitda":-118991000,"period":"2025-12-31","revenue":281266000,"epsBasic":-1,"netIncome":-128494000,"rdExpense":98264000,"epsDiluted":-1,"grossProfit":181774000,"operatingIncome":-120805000},{"sga":180641000,"ebit":-91646000,"ebitda":-82238000,"period":"2025-09-30","revenue":265196000,"epsBasic":-0.74,"netIncome":-92725000,"rdExpense":89957000,"epsDiluted":-0.74,"grossProfit":171609000,"operatingIncome":-98989000},{"sga":169847000,"ebit":-98878000,"ebitda":-88836000,"period":"2025-06-30","revenue":232088000,"epsBasic":-0.8,"netIncome":-99899000,"rdExpense":87449000,"epsDiluted":-0.8,"grossProfit":150883000,"operatingIncome":-106413000},{"sga":151268000,"ebit":-94078000,"ebitda":-83842000,"period":"2025-03-31","revenue":203471000,"epsBasic":-0.77,"netIncome":-95159000,"rdExpense":88521000,"epsDiluted":-0.77,"grossProfit":128748000,"operatingIncome":-111041000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":98.23,"previousClose":98.47,"fiftyTwoWeekHigh":120.74,"fiftyTwoWeekLow":36.36,"fiftyTwoWeekRange":"36.36 - 120.74","fiftyDayAverage":88.99,"twoHundredDayAverage":85.53,"beta":1.49,"enterpriseValue":13658910720,"forwardPE":-155,"priceToBook":-71.34,"priceToSales":12.06,"enterpriseToRevenue":12.64,"enterpriseToEbitda":-33.47,"pegRatio":0,"ebitda":-408155008,"ebitdaMargin":-37.8,"freeCashflow":-85448128,"operatingCashflow":-187694000,"totalDebt":1704556032,"debtToEquity":0,"currentRatio":4.68,"returnOnAssets":-17.1,"returnOnEquity":0,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":20,"targetMeanPrice":130.55,"targetHighPrice":190,"targetLowPrice":90,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.1,"institutionHeldPercent":100.8,"sharesOutstanding":132599929,"floatShares":127179244,"sharesShort":12806414,"shortRatio":5.74,"shortPercentOfFloat":9.7,"epsTrailing":-3.4,"epsForward":-0.63,"revenuePerShare":8.49,"bookValue":-1.38,"officers":[{"age":46,"name":"Dr. Helmy  Eltoukhy Ph.D.","title":"Co-Founder, Co-CEO & Chairman"},{"age":45,"name":"Dr. AmirAli  Talasaz Ph.D.","title":"Co-CEO & Director"},{"age":56,"name":"Mr. Michael  Bell","title":"Chief Financial Officer"},{"age":51,"name":"Dr. Darya  Chudova","title":"Chief Technology Officer"},{"age":52,"name":"Mr. John G. Saia J.D.","title":"Chief Legal Officer & Corporate Secretary"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://guardanthealth.com","phone":"855 698 8887"}}